BTG2 expression is decreased in various tumor tissues such as breast cancer, lung cancer, bladder cancer and HCC [18–21], and the low expression of BTG2 is associated with the aggressive clinical manifestations and poor prognosis [10, 11, 22]. This evidence concerns the gene BTG2 and hepatocellular carcinoma.